Benzinga | Aug 4, 2021 09:18AM EDT

Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to $110

Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and lowers the price target from $116 to $110.